News & Updates

High-dose somatostatin analogues (SSAs) can be effective and well-tolerated second-line therapies in neuroendocrine tumours (NETs) progressing on standard-dose SSAs in selected cases, according to Dr Ingrid Mak of the University of Hong Kong, at the 7th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2024). 

Interim data from a phase II trial demonstrate the safety and tolerability of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in adolescents. MVA-BN is a live attenuated, non-replicating orthopoxvirus vaccine licensed in the US for smallpox and mpox prevention.

Children attending day care appear to be less likely than those who do not to have type 1 diabetes (T1D), according to the results of a meta-analysis.

Once-weekly treatment with islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor, led to sustained high rates of viral suppression at week 48 among people with HIV, according to the secondary endpoint results of a phase II study presented at IDWeek 2024.

New drug applications approved by US FDA as of 1-15 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Early intratracheal budesonide in extremely preterm infants receiving surfactant for respiratory distress syndrome appears to be of little to no benefit in terms of survival free of bronchopulmonary dysplasia (BPD), according to a study.